New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
16:46 EDTIMUCImmunoCellular presents updated ICT-107 Phase II data
ImmunoCellular Therapeutics announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme, GBM, were presented at the 2014 American Society for Clinical Oncology, ASCO, annual meeting in Chicago. When overall survival. OS, and progression-free survival, PFS, were assessed in pre-specified patient subgroups, results favored treatment with ICT-107 over control in HLA-A2 patients within each of the two major MGMT subgroups. While the subgroups were small in size, and not powered to show statistical significance, the numeric advantages in favor of ICT-107 treated patients were shown to be large and clinically meaningful. HLA, human leukocyte antigens, are cell-surface antigen-presenting proteins. These molecules are on dendritic cells and present the tumor-associated antigens to T-cells to induce the immune response to the ICT-107 vaccine. HLA-A2 was one of two HLA types that were treated in the phase II trial. Of the two types, HLA-A2 is twice as common in the population as HLA-A1, and is the most common HLA type in North America and the EU.
News For IMUC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
16:23 EDTIMUCImmunoCellular to hold a conference call on ICT-107
Subscribe for More Information
November 20, 2015
06:05 EDTIMUCImmunoCellular presents updated ICT-107 Phase 2 immune response data
ImmunoCellular Therapeutics announced the presentation of recently updated overall survival, or OS, results and immune response data from the phase 2 trial of ICT-107 in patients with newly diagnosed glioblastoma. ICT-107 is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. The data are being presented at the 20th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology, being held in San Antonio, TX. The data from the phase 2 trial continue to indicate a survival advantage in the ICT-107 treated group compared to the control group. The data also show a significant association between immune response and survival, especially in HLA-A2 positive, or HLA-A2+, patients, which is the target patient population for the phase 3 registration trial.
November 12, 2015
06:05 EDTIMUCImmunoCellular enters sponsored research agreement with MD Anderson
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use